Stuart Diamond: ApoB as a Key Marker of Cardiovascular Risk
Stuart Diamond, Scientific Director at Global Integral Beauty, Medical Doctor at Geneva College of Longevity Science, and Co-Founder at Equilux – Unlock Your Biology, shared a post on LinkedIn:
“For decades, cardiovascular risk has been assessed primarily through LDL-cholesterol.
But modern lipid science increasingly points to a more fundamental driver of atherosclerosis:
Apolipoprotein B (ApoB).
Every atherogenic lipoprotein particle – LDL, VLDL remnants, IDL, and Lp(a) – carries one ApoB molecule.
This means ApoB reflects the number of particles capable of penetrating the arterial wall and initiating plaque formation.
Two individuals can have identical LDL- C levels, yet one may have significantly more circulating atherogenic particles.
In simple terms:
- LDL-C measures cholesterol content.
- ApoB measures particle number.
Evidence continues to support this.
- Ference BA et al., European Heart Journal (2017) — genetic analyses showing cardiovascular risk proportional to cumulative exposure to ApoB lipoproteins.
- Sniderman AD et al., JAMA Cardiology (2019) — ApoB more accurately reflects atherogenic particle burden than LDL-C.
- Yusuf S et al., Lancet — INTERHEART study linking ApoB/ApoA1 ratio to myocardial infarction risk globally.
From a biological perspective the mechanism is straightforward.
Atherosclerosis begins when ApoB-containing lipoproteins cross the endothelium and become retained in the arterial intima, triggering inflammation and plaque formation.
The greater the number of circulating ApoB particles, the greater the probability of this process occurring.
Cardiovascular disease still remains the leading cause of mortality worldwide, often developing silently for decades.
Monitoring ApoB allows clinicians to detect and address risk earlier and more precisely.
Preventive targets commonly used in cardiology practices include:
- ApoB less than 80 mg/dL – moderate risk
- ApoB less than 60 mg/dL – high-risk prevention
- ApoB less than 50 mg/dL – aggressive prevention
Achieving these levels often requires lifestyle optimization and targeted therapy including statins, ezetimibe, PCSK9 inhibitors, or bempedoic acid.
What is becoming increasingly clear:
Atherosclerosis is fundamentally a disease of cumulative exposure to ApoB-containing particles.
Reducing that exposure earlier in life may be one of the most powerful ways to extend cardiovascular health and healthspan.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 13:25Wolfgang Miesbach: Platelet Variation and How Do They Move Over Time?
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia
-
Apr 15, 2026, 12:27Laurent Bertoletti: Joining Global Experts to Improve Thrombosis Care in Cancer for the ICTHIC 16th Edition
-
Apr 15, 2026, 12:13Francesco Antonio Veneziano: JCDD MDPI Calls for Papers on Advances in Thrombosis and Antithrombotic Therapy
-
Apr 15, 2026, 11:05Julius Kyei Baffour: Understanding Thrombophilia Testing and Patient Risk
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care